219 related articles for article (PubMed ID: 32039550)
1. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
2. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
[TBL] [Abstract][Full Text] [Related]
3. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
4. Assessment of low plasma concentrations of apixaban in the periprocedural setting.
Lessire S; Dincq AS; Siriez R; Pochet L; Sennesael AL; Vornicu O; Hardy M; Deceuninck O; Douxfils J; Mullier F
Int J Lab Hematol; 2020 Aug; 42(4):394-402. PubMed ID: 32297711
[TBL] [Abstract][Full Text] [Related]
5. Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.
Jensen KOF; Hansen SH; Goetze JP; Jesting A; Stensballe J; Hansen H
Eur J Haematol; 2017 Nov; 99(5):431-436. PubMed ID: 28833682
[TBL] [Abstract][Full Text] [Related]
6. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
[TBL] [Abstract][Full Text] [Related]
7. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
9. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
[TBL] [Abstract][Full Text] [Related]
10. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
[TBL] [Abstract][Full Text] [Related]
11. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
[TBL] [Abstract][Full Text] [Related]
12. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
[TBL] [Abstract][Full Text] [Related]
13. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Goto E; Horinaka S; Ishimitsu T; Kato T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
[TBL] [Abstract][Full Text] [Related]
14. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
17. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
18. Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.
Lin SY; Kuo CH; Yeh SJ; Tsai LK; Liu YB; Huang CF; Tang SC; Jeng JS
Clin Pharmacol Ther; 2020 Jan; 107(1):278-286. PubMed ID: 31376150
[TBL] [Abstract][Full Text] [Related]
19. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
[TBL] [Abstract][Full Text] [Related]
20. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.
Becker RC; Yang H; Barrett Y; Mohan P; Wang J; Wallentin L; Alexander JH
J Thromb Thrombolysis; 2011 Aug; 32(2):183-7. PubMed ID: 21516308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]